Topics

Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type.PERSEIDA Study

2016-06-07 16:08:21 | BioPortfolio

Summary

Analysis of freely circulating DNA in liquid biopsies using the BEAMing method

Description

Analysis of freely circulating DNA in liquid biopsies using the BEAMing method is proposed as a technique that may be useful for analysing the RAS mutation status in different types of cancer. However, first it is necessary to evaluate the concordance between the results obtained in tumour samples and liquid biopsies.

Primary objective

• To evaluate the RAS mutation status at baseline in liquid biopsies in subjects with RAS wild-type metastatic colorectal cancer.

Secondary objectives

- To evaluate the appearance of new RAS mutations using liquid biopsies at the moment of disease progression.

- To evaluate the appearance of new RAS mutations using liquid biopsies prior to radiological documentation of disease progression.

Study Design

Time Perspective: Prospective

Conditions

RAS Wild Type mCRC

Location

Research Site
Almeria
Andalucía
Spain
04009

Status

Recruiting

Source

Amgen

Results (where available)

View Results

Links

Published on BioPortfolio: 2016-06-07T16:08:21-0400

Clinical Trials [384 Associated Clinical Trials listed on BioPortfolio]

FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status

To estimate progression-free survival at one year in elderly patients with RAS/BRAF wild-type unresectable mCRC and good performance status treated with FOLFIRI + panitumumab as first-line...

Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC

The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR Monoclonal antibody(SCT200)in patients with wild-type RAS and BRAF mCRC treated with fluoroura...

A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC

This trial is conducted in patients with the recurrent lesion(s) post-surgery or the untreated mCRC. After stratification with respect to ECOG PS score, chemo regimen, primary tumor locati...

Panitumumab Combination Study With AMG 102 or AMG 479 in Wild-type KRAS mCRC

This study is a global, multicenter, open-label phase 1b and randomized, double-blinded, 2 part, phase 2 study designed to evaluate the safety and efficacy of AMG 102 or AMG 479 in combina...

Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal

To estimate progression-free-survival at 6 months in subjects treated in first-line with panitumumab and FOLFOX and with wild type RAS mCRC confirmed in liquid biopsies before starting sec...

PubMed Articles [8901 Associated PubMed Articles listed on BioPortfolio]

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.

Cetuximab is a standard-of-care treatment for RAS wild-type metastatic colorectal cancer (mCRC) but not for those harbor a KRAS mutation since MAPK pathway is constitutively activated. Nevertheless, c...

Ongoing and future directions in the management of metastatic colorectal cancer: Update on clinical trials.

Metastatic colorectal cancer (mCRC) continues to show poor outcomes, with many patients exhausting effective standard-of-care therapy. To explore the current landscape of clinical trials for mCRC, we ...

Treatment sequencing in metastatic colorectal cancer.

Metastatic colorectal cancer (mCRC) remains incurable in most cases, but survival has improved with advances in cytotoxic chemotherapy and targeted agents. However, the optimal use and sequencing of t...

Competition in the Chemostat with an Undesirable Lethal Competitor.

In this study, we compare the effects of competitors in a chemostat when one of the competitors is lethal to the other. The first competitor ("the mutant") is the desired organism because it provides ...

A case of panitumumab containing chemotherapy causing interstitial lung disease: early recognition and treatment resulting in a good outcome.

Panitumumab is a recombinant human IgG monoclonal antibody which is used for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or following FOLFIRI (fluoro...

Medical and Biotech [MESH] Definitions

Animals considered to be wild or feral or not adapted for domestic use. It does not include wild animals in zoos for which ANIMALS, ZOO is available.

A genus of the family RETROVIRIDAE with type C morphology, that causes malignant and other diseases in wild birds and domestic fowl.

The type species of ORBIVIRUS causing a serious disease in sheep, especially lambs. It may also infect wild ruminants and other domestic animals.

The type species of the genus MARDIVIRUS in the family HERPESVIRIDAE. It is the etiologic agent of MAREK DISEASE, infecting domestic fowl and wild birds.

An order of insects comprising the chewing lice or biting lice, many of which are parasitic on wild birds and domestic fowl and on wild and domestic mammals. Suborders include Amblycera and Ischnocera.

More From BioPortfolio on "Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type.PERSEIDA Study"

Quick Search

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Searches Linking to this Trial